RAC has always been excellent in controlling the bisantrene narrative. The change in focus from bisantrene (the compound) to Zantrene (the marketable product) demonstrates the shift from a pre/clinical research focus to BP transaction.
I think it's unlikely that it will be RAC who completes this trial.
RAC has always been excellent in controlling the bisantrene...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.020(1.31%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.60 | $1.53 | $79.54K | 51.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.60 | 23239 | 1 |
View Market Depth
| Last trade - 15.57pm 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |